SKLB-23bb,1815580-06-3

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

SKLB-23bb

CAS No. : 1815580-06-3

MCE 国际站：SKLB-23bb

产品活性：SKLB-23bb 是一种有效的选择性 HDAC6 抑制剂，IC₅₀ 为 17 nM，比抑制 HDAC1 (IC₅₀= 422 nM) 和 HDAC8 (IC₅₀=3398 nM) 选择性分别高 25 倍和 200 倍。

研究领域：Cell Cycle/DNA Damage  |  Epigenetics

作用靶点：HDAC

In Vitro: SKLB-23bb (Compound 23bb) presents low nanomolar antiproliferative effects against panel of cancer cell lines. The antiproliferative activity is ton human malignant melanoma A375 cells and cervical cancer HeLa cells, SKLB-23bb shows the most potent activities with IC₅₀ values of 50 and 49 nM on A375 and HeLa cells, respectively. The antiproliferative activities against 11 kinds of hematological tumors (myelomaU266, RPMI8226 cells, human leukemia MV4-11, K562 cells, and human B cell lymphoma Ramos cells) or solid tumors (ovarian cancer A2780s, SKOV-3 cells, breast cancer SKBR3 cells, liver cancer HepG2 cells, lung cancer H460, A549 cells, cervical cancer HeLa cells and colon cancer HCT116, HT29 cells) cell lines of SKLB-23bb are evaluated by MTT, and the SAHA and ACY-1215 are as positive control. SKLB-23bb shows significant antiproliferative potential with the IC₅₀ values ranging from 14 to 104 nM in these tumor cell lines.

In Vivo: SKLB-23bb (Compound 23bb) reduces the tumor growth in both the hematological tumor MV4-11 xenograft model and solid tumor HCT116 xenograft model. The significant antitumor activities are observed by intravenous administration of SKLB-23bb at 50 mg/kg on MV4-11 and HCT116 xenograft models. The growth of MV4-11 and HCT116 cancer cell xenografts is suppressed by 55.0% and 76.3% (percent of tumor mass change [TGI] values) after iv administration of SKLB-23bb at 50 mg/kg. The HCT116 xenograft model is also established to investigate the antitumor activity of oral administration of SKLB-23bb. The TGI value of oral administration of SKLB-23bb (25 mg/kg) on HCT116 xenograft model is 60.4%, which is superior to the SAHA group (100 mg/kg, 59.2%). Additionally, the body weight decrease is acceptable and no other adverse effects are observed upon treatment with SKLB-23bb. Low clearance (CL=7.008 L/kg per hour for iv, CL=12.877 L/kg per hour for po) and long terminal half-life (t_1/2=7.658 h for iv, t_1/2=9.62 h for po) are observed in SKLB-23bb. The oral bioavailability of SKLB-23bb is excellent in rats and the bioavailability is up to 47.0%.

相关产品：Bioactive Compound Library Plus  |  Trichostatin A  |  Vorinostat  |  4-Phenylbutyric acid  |  Valproic acid  |  Sulforaphane  |  Panobinostat  |  Entinostat  |  Romidepsin  |  Tucidinostat  |  RGFP966  |  Belinostat  |  Ricolinostat  |  Tubastatin A  |  TMP195  |  Theophylline  |  Carbamazepine  |  Mocetinostat  |  Santacruzamate A  |  ITSA-1  |  TMP269  |  Tasquinimod  |  Fimepinostat  |  Tubacin  |  LMK-235  |  Quisinostat  |  PCI-34051  |  FT895

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds